Airway Remodeling Biomarkers in Preclinical Lung Disease

Abstract

Airway remodeling is a hallmark of chronic lung diseases such as asthma, chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF), often preceding the onset of overt clinical symptoms. The identification of reliable biomarkers for airway remodeling in preclinical stages holds promise for early diagnosis, risk stratification, and targeted therapeutic interventions. This review synthesizes current evidence on the epidemiology, pathophysiological mechanisms, risk factors, clinical manifestations, diagnostic strategies, management approaches, recent advances, and guideline recommendations for airway remodeling biomarkers in preclinical lung disease, with a focus on the translational potential of these markers in clinical practice.

Introduction

Chronic lung diseases remain a leading cause of morbidity and mortality worldwide. Airway remodeling, characterized by structural alterations in the airway wall, contributes significantly to disease progression and treatment resistance. The early detection of these changes, before the onset of irreversible functional loss, is critically dependent on the identification of sensitive and specific biomarkers. This review aims to elucidate the current landscape of airway remodeling biomarkers in preclinical lung disease, drawing from recent PubMed-indexed studies and expert consensus guidelines to inform clinical practice and future research directions.

Epidemiology / Disease Burden

Chronic respiratory diseases, including asthma and COPD, impact hundreds of millions globally. Airway remodeling is present in up to 80% of patients with chronic airway diseases, often beginning during subclinical phases. Early remodeling changes have been documented in at-risk populations such as smokers, individuals with occupational exposures, and genetically predisposed cohorts. The global burden is exacerbated by underdiagnosis in the preclinical stage, contributing to progressive airflow limitation and increased healthcare utilization. Epidemiological studies highlight the need for biomarkers that can identify at-risk individuals prior to symptom onset, particularly in populations with high environmental or genetic risk.

Pathophysiology

Airway remodeling encompasses a complex interplay of epithelial injury, inflammatory cell infiltration, extracellular matrix (ECM) deposition, smooth muscle hypertrophy, goblet cell hyperplasia, and neovascularization. These changes are orchestrated by a network of cytokines, growth factors (e.g., TGF-β, VEGF), proteases, and microRNAs. Distinct molecular signatures precede morphological alterations and can be detected in biological fluids such as blood, sputum, exhaled breath condensate, and bronchoalveolar lavage. Biomarkers such as periostin, YKL-40, matrix metalloproteinases (MMPs), and exosomal microRNAs reflect underlying mechanisms of remodeling and may serve as early indicators of disease activity.

Risk Factors

Key risk factors for airway remodeling include genetic predisposition (e.g., polymorphisms in ADAM33, IL-13, TGF-β1), environmental exposures (tobacco smoke, pollutants, occupational allergens), early-life respiratory infections, and poorly controlled airway inflammation. A family history of asthma or COPD, recurrent childhood wheezing, and atopy increase susceptibility. Comorbidities such as obesity, gastroesophageal reflux, and metabolic syndrome have also been implicated in accelerating remodeling processes. Understanding these risk factors enhances the predictive value of biomarker-based screening in asymptomatic or minimally symptomatic individuals.

Clinical Features

In the preclinical phase, airway remodeling is often clinically silent, though subtle features may include mild airflow limitation on spirometry, increased airway hyperresponsiveness, or minor radiographic abnormalities. Biomarker elevation may precede these changes, providing an opportunity for early intervention. In advanced stages, patients develop persistent symptoms such as cough, wheeze, exertional dyspnea, and fixed airway obstruction. The challenge lies in differentiating early remodeling from transient inflammatory changes, underscoring the need for robust biomarkers with high sensitivity and specificity.

Diagnosis

Current diagnostic approaches rely on imaging (high-resolution CT), pulmonary function testing, and invasive sampling (bronchoscopy, biopsy). However, these methods have limitations in sensitivity and feasibility for widespread screening. Biomarkers detectable in non-invasive samples are an area of active investigation. Periostin, YKL-40, MMP-9, exhaled nitric oxide, and microRNAs (e.g., miR-21, miR-155) have shown promise in delineating remodeling activity. Multi-omic strategies integrating genomics, proteomics, and metabolomics are enhancing diagnostic accuracy. The validation of biomarker panels is ongoing in prospective cohorts, with the aim of establishing cut-offs for clinical use.

Treatment & Management

Although no therapies currently reverse established airway remodeling, early identification through biomarkers may enable preventive strategies. Inhaled corticosteroids, biologics targeting type 2 inflammation (e.g., anti-IL-5, anti-IL-13), and agents modulating ECM turnover are under investigation for their impact on remodeling pathways. Smoking cessation, allergen avoidance, vaccination, and optimal control of airway inflammation remain cornerstones of prevention. Tailoring therapy based on biomarker profiles so-called precision medicine may improve outcomes in individuals identified at the preclinical stage.

Recent Advances / Emerging Therapies

Advances in high-throughput molecular profiling have accelerated the discovery of novel biomarkers such as extracellular vesicle cargo, volatile organic compounds, and epigenetic signatures. Longitudinal studies are evaluating the predictive value of combined biomarker panels for incident airway disease. Novel therapeutic approaches include anti-fibrotic agents, inhibitors of TGF-β signaling, and regenerative strategies targeting airway progenitor cells. Several clinical trials are assessing whether biomarker-guided intervention in at-risk populations can prevent progression to overt disease.

Guideline Recommendations

International guidelines from bodies such as the Global Initiative for Asthma (GINA) and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) emphasize the importance of early detection and risk stratification. While biomarker-based screening is not yet standard of care, guidelines support research use in high-risk cohorts and endorse the integration of validated biomarkers into future diagnostic algorithms. Ongoing updates are anticipated as more evidence emerges regarding the clinical utility of these tools.

Conclusion

The study of airway remodeling biomarkers in preclinical lung disease is a rapidly evolving field with significant implications for early diagnosis, prevention, and tailored therapy. As the spectrum of available biomarkers expands, their integration into clinical practice will depend on robust validation, standardization, and demonstration of impact on patient outcomes. Collaborative efforts between basic scientists, clinicians, and regulatory agencies are critical to translating these advances into improved care for individuals at risk of chronic respiratory diseases.